Cambrex Corporation (CBM)’s Financial Results Comparing With Tenax Therapeutics Inc. (NASDAQ:TENX)

Cambrex Corporation (NYSE:CBM) and Tenax Therapeutics Inc. (NASDAQ:TENX) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cambrex Corporation 60 1.88 33.43M 2.30 19.05
Tenax Therapeutics Inc. 1 0.00 6.30M -7.65 0.00

In table 1 we can see Cambrex Corporation and Tenax Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Cambrex Corporation 55,921,712.95% 12.1% 6.6%
Tenax Therapeutics Inc. 517,198,916.35% -175.2% -156.5%

Volatility & Risk

Cambrex Corporation is 135.00% more volatile than S&P 500 due to its 2.35 beta. Tenax Therapeutics Inc. on the other hand, has 1.4 beta which makes it 40.00% more volatile compared to S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Cambrex Corporation are 3 and 2. Competitively, Tenax Therapeutics Inc. has 11 and 11 for Current and Quick Ratio. Tenax Therapeutics Inc.’s better ability to pay short and long-term obligations than Cambrex Corporation.

Analyst Recommendations

Cambrex Corporation and Tenax Therapeutics Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cambrex Corporation 0 1 0 2.00
Tenax Therapeutics Inc. 0 0 0 0.00

Cambrex Corporation has a consensus price target of $60, and a 0.02% upside potential.

Institutional & Insider Ownership

Cambrex Corporation and Tenax Therapeutics Inc. has shares owned by institutional investors as follows: 0% and 22.2%. About 1% of Cambrex Corporation’s share are owned by insiders. Comparatively, 4.73% are Tenax Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cambrex Corporation -3.01% -5.09% 1.69% -1.88% -28.61% 16%
Tenax Therapeutics Inc. -2.96% -6.43% -21.56% 11.97% -79.3% 8.26%

For the past year Cambrex Corporation was more bullish than Tenax Therapeutics Inc.

Summary

Cambrex Corporation beats on 9 of the 12 factors Tenax Therapeutics Inc.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.